Covid-19 asi funciona remdesivir...

 

Obama y la PhRMA "van juntos"...

Los republicanos en la cámara de Representantes pusieron al descubierto correos electrónicos y otros documentos que muestran cómo la administración de Obama coordinó 150 millones de dólares de campaña publicitaria en favor de la reforma con importantes empresas farmacéuticas.

Casi 70 millones de dólares fueron gastados a través de dos Super PA -comités de acción política- organizados en parte por funcionarios de la Casa Blanca, incluyendo a Jim Messina, ex jefe de despacho de la presidencia que conduce actualmente la campaña en favor de su reeleccón de Obama en los comicios de noviembre próximo.

Notas divulgadas el viernes desde el comité de Energía y Comercio de la cámara revelan los estrechos lazos existentes entre la administración de Obama y la Pharmaceutical Research and Manufacturers of America, también conocida como PhRMA.

Más

CHILE: US$ 2 mil millones en juego/Guerra de farmacéuticas

US$ 2 mil millones en juego. Si lo prefiere, casi $ 1.000.000.000.000 y aumentando cada año. Así de grande es el mercado de los medicamentos en Chile.

Por eso, no es de extrañar que se esté librando a todo nivel una soterrada batalla entre laboratorios nacionales y multinacionales, especialmente estadounidenses: En La Moneda, el Congreso, la Cancillería, en Contraloría, en los ministerios de Salud, de Economía, en servicios públicos, embajadas, foros internacionales, en tribunales...

Si los norteamericanos hasta han patrocinado, auspiciado y organizado cursos para jueces y fiscales chilenos en materias de "protección intelectual", según documentos a los que accedió «La Segunda Sábado».

El problema se resume en que la industria farmacéutica nacional sóloproduce remedios genéricos (copias de los originales cuyas patentes han vencido), algo que si bien no aporta al avance científico mundial, sí ayuda a tener precios y acceso razonable a estos productos en el país. Pero los grandes laboratorios internacionales , que sí hacen multimillonarias investigaciones para crear nuevas fórmulas que combatan enfermedades, quieren más protección o, al menos, mecanismos más eficientes que dificulten la competencia de los genéricos, sobre todo si estos últimos llegasen a irrespetar una patente.

Así, con tantos millones de dólares en juego sobre la mesa, se desarrolla un poderoso lobby desde Estados Unidos para que Chile realice cambios legales según sus intereses, algunos de ellos mediante un acuerdo comercial que se negocia en total reserva y que -alega la industria chilena- podría fijar nuevos criterios para proteger aún más a la industria de los innovadores.

Batalla 1: El linkage y la trampa de la "lista roja"

"Pensamos que podíamos jugar con reglas claras, pero hay ciertas trampitas, vacíos", se queja el presidente de la Cámara de la Innovación Farmacéutica de Chile (CIF), Richard Nevares . La entidad agrupa a los grandes laboratorios norteamericanos y algunos europeos, y aboga para que el Congreso apruebe el proyecto conocido como Linkage.

La iniciativa crea un nuevo mecanismo -más rápido- para sacar de circulación a los medicamentos sospechosos de vulnerar alguna patente, otorgándole atribuciones al Instituto de Salud Pública (ISP) en la materia, como instancia previa a los tribunales. La idea despierta reparos transversales entre parlamentarios y laboratorios nacionales y ahora el Gobierno le quitó la urgencia que le puso para discutirlo en la Cámara.

.../...

Batalla 2: Negociaciones en reserva

Pero aunque fracase el proyecto de Linkage, existe un tratado comercial que en estos momentos negocia Chile con Estados Unidos y otros países, que no sólo contendría una forma de Linkage, sino que, además, protección adicional para la industria de los medicamentos innovadores, que podría significar para ella miles de millones de dólares en potenciales ganancias: El Trans Pacific Partnership (TPP).

Uno de los aspectos que se negocia es dar tratamiento de información no divulgada a las segundas indicaciones de los medicamentos durante cinco años. Ejemplo: El sildenafil (más conocido por la marca viagra) era para la presión arterial y angina de pecho, pero se le descubrió una segunda indicación o uso que comercialmente fue más rentable.

Estados Unidos pretende que en el TPP se consagre que quien descubra esa segunda o tercera nueva indicación reciba protección, para que todos los estudios que se hicieron para el hallazgo no puedan ser utilizados por otras empresas de la industria farmacéutica por cinco años. O sea, que no se pueda recetar otras marcas que la protegida para combatir el mal cubierto por el segundo uso.

Los laboratorios chilenos no desean eso, porque no tienen las espaldas financieras para realizar sus propias investigaciones y no quieren perder mercado.

"Una cosa es liberar aranceles y otra distinta es establecer restricciones adicionales a patentes y derechos de autor, porque pueden tener impacto en la política nacional de medicamentos y encarecer los precios", señala el senador Chahuán.

Más

Ver también:

Citario/El dijo que...: John Mack sobre PhRMA & S.O.P.A.

Cuadro de "Des_Honor" por "Malas Prácticas" de Marketing.

With Abbott’s $1.5 billion settlement of a whistleblower-initiated case this week, Abbott joins an infamous list of pharma companies that have paid more than one billion dollars to the federal government for illegal marketing practices, including promoting prescription drugs for uses not approved by the FDA, paying financial inducements to increase sales and engaging in practices that pose grave danger to patients’ health and lives.

This dishonor roll includes pharma giants Pfizer, which paid $2.3 billion to the government in 2009, and Eli Lilly, which settled civil and criminal charges earlier in 2009 for $1.4 billion.

Soon there will be more additions to pharma’s billion-dollar-plus club: GlaxoSmithKline announced last November that it had reached an agreement in principle to pay $3 billion this year to resolve multiple government investigations into its sales and marketing practices. And Johnson & Johnson (J&J ) reportedly is in negotiations with the government to pay more than $1 billionto settle civil charges for the off-label marketing of Risperdal and Invega.

.../...

Yet the Pharmaceutical Research and Manufacturers of America (PhRMA), the major pharma lobbying group, claims its members are “committed to following the highest ethical standards and al legal requirements,” according to PhRMA’s website. To demonstrate this, PhRMA members developed the “Code on Interactions with Healthcare Professionals,” which states that:

"Ethical relationships with healthcare professionals are critical to our mission of helping Patients . . . An important part of achieving this mission is ensuring that healthcare professionals have the latest, most accurate information available regarding prescription medicines.”

It is no small irony that nearly 60 pharma companies — including Abbott,Pfizer, Eli Lilly, Glaxo, J&J and Amgen – are signatories to the code. For at least three of them — Abbott, Pfizer and Eli Lilly – the PhRMA code was in place while they committed these billion-dollar-plus violations. (The details of the Glaxo, J&J and Amgen cases haven’t been announced yet since the whistleblower cases that started the government investigations are not public.)

The disconnect between the self-serving proclamations of “high ethical standards” and the reality of pharma’s conduct is vast. In Abbott’s case, the Justice Department press release states that “Not only did Abbott engage in off-label promotion, but it targeted elderly dementia patients and downplayed the risks apparent from its own clinical studies.”

Más

Ver también:

ABBOTT paga...$1.6 billion

Multas...

BIG PHARMA’S CRIME SPREE

The Worst Drug Company Marketing Techniques (I): PFIZER

"Off-Label Promotion": La historia interminable...

USA: Pharma Lobbying Spending.

According to Open Secrets, which tracks industry lobbying, "the pharmaceutical industry as a whole spent $69.6 million on lobbying in the first three months" of 2012 (see "Pharma, Utilities and Big Ag Lead Lobbying in 2012"). Included in that category are "Health products" other than Rx medicines. Looking at just "Pharmaceutical Manufacturers" (including PhRMA, the drug industry's U.S. trade association), the total lobbying spend in the first quarter of 2012 was $48.1 million.

Here's a chart of the biggest spenders in this category so far:

Annual pharmaceutical lobbying -- as measured in dollars -- increased more or less steadily since 1998, but peaked in 2009 at $186.1 million. If the spending in 2012 continues at the pace of the first three months, the pharmaceutical industry will spend approximately $192.4 million in lobbying for the year (see chart; the 2012 bar is projected as 4 X Q1).


Gracias a John Mack/Pharma Marketing Blog

Ver también:

Asi es el ´lobby´ de la industria farmacéutica en Europa: 40 millones de €

A "Wiki" ( y a Google, y al "Feis"...) tampoco le gusta la sopa...

Click sobre imagen para ampliar.



Y a...


Las redes sociales "si pueden"...

Antes y después del "paro digital"


Ver también:

Y qué es la S.O.P.A....'

Citario/El dijo que...: John Mack sobre PhRMA & S.O.P.A.

Y qué es la S.O.P.A...?

“This is the first real test of the political strength of the Web, and regardless of how things go, they are no longer a pushover,” said Professor Wu, who is the author of “The Master Switch: The Rise and Fall of Information Empires.” He added, “The Web taking a stand against one of the most powerful lobbyers and seeming to get somewhere is definitely a first.”

Citario/El dijo que...: John Mack sobre PhRMA & S.O.P.A.

Citario/El dijo que...: John Mack sobre PhRMA & S.O.P.A.

"Why do Pfizer and PhRMA support these bills? Simple. They believe it is necessary to prevent "counterfeit" medicines from being sold to US consumers by companies outside the US. At least that's why I think they are supporting these bills. I don't find any press releases or blog posts about it on Pfizer's or PhRMA's site. Perhaps they will respond to this post and tell us in their own words why?

If the industry needs help from the government to prevent counterfeit medicines from reaching US consumers, why not support specific laws for that purpose instead of this legislation that potentially can be used to limit the rights without due process of many online publishers -- who do not have anything to do with counterfeit medicine."

John Mack es editor de Pharma Marketing News

Ver también:

Big PHARMA / PhRMA hasta en la S.O.P.A....(III)

Big PHARMA / PhRMA hasta en la S.O.P.A....(III)

PhRMA senior VP Matthew Bennett had issued a statement in October expressing the trade group's support for the bill. "PhRMA applauds the introduction of the Stop Online Piracy Act and looks forward to working with Chairman Smith and members of the House Judiciary Committee on an issue critical to innovation in the U.S.," he wrote.

"America's pharmaceutical research and biotechnology companies invest billions of dollars each year researching and developing new medicines, and they depend on strong and reliable IP protections to continue their important work in research labs across the nation. Intellectual property rights afforded to America's pharmaceutical research companies help them recoup their incredible investments in the discovery of new medicines, and give them a chance to survive and fund further research in a highly competitive environment."

In testimony before the House Judiciary Committee, John Clark, Pfizer chief security officer, said passage of the bill is essential to protect U.S. consumers from knockoff "In trying economic times, it is important that sound policies support America's innovative industries - which employ millions of Americans - by protecting the intellectual property on which they depend." drugs that are potentially harmful. "For Pfizer, pharmaceutical counterfeiting is first and foremost an issue of patient health and safety," said Clark.

Ver anterior:

Big PHARMA / PhRMA hasta en la S.O.P.A....(II)

Big PHARMA / PhRMA hasta en la S.O.P.A....(II)

There is NO debate what-so-ever that the alternative media is putting a huge dent not only into the profit margins of the large pharmaceutical companies BUT, that’s not all. What really has big pharma hop’n mad is that the information and choice that people now have, thanks to the internet, ‘removed the spell’, so-to-speak, that people have been under, where ONLY big pharma drugs and treatments can heal you from illness, disease and the big one, cancer. People are finding alternatives AND preventive measures over the internet THAT WORK and the large pharmaceutical companies won’t stand for that.

Big pharma, that makes up the main body of people at the FDA, have used that ‘unelected by the people’ bureaucratic office to shut down so many ‘truly healthy’ entities ranging from raw almond production to the ability of blue berry producers RIGHT to present the science FACTS of blue berries healthy impact on the human body, while on the other hand, ALWAYS green lighting dangerous and EXPERIMENTAL drugs. The example of how big pharma’s ‘VERY OWN’ FDA restricting Americans healthy alternative to dangerous pharmaceuticals are too numerous to list in this article but, are in abundance both sourced and documented ON LINE that it would take weeks to read about it all.

That brings us back to the topic at hand, the internet and, big pharma doing their part in TAKING AWAY YOUR RIGHT TO READ THAT INFORMATION SO YOU CAN MAKE AN INFORMED CHOICE. Part of that plan is to gain control of the internet so those with vested interest can wipe out websites like this one with no judge, no jury, simply by going to (in the case of USA) a federal attorneys office with a ‘FRIVOLOUS’ complaint. This has actually already happened. The bill(s) would make it much harder for the innocent to seek retribution. (Más)

Group 1 Big Pharma backed companies.

Alliance for Safe Online Pharmacies (ASOP)

Pfizer, Inc

American Pharmacists Association*
European Alliance for Access to Safe Medicines
Eli Lilly & Company*
International Pharmaceutical Federation
Wolters Kluwer Health (Information on Pharmaceuticals)
LegitScript*
National Association of Chain Drug Stores*
NeedyMeds
Enforce the Act
Partnership at Drug-Free.org

National Association of Boards of Pharmacy
National Health Council
Partnership for Safe Medicines
Pharmaceutical Research and Manufacturers of America (PhRMA)

Ver anterior:

Big PHARMA / PhRMA hasta en la S.O.P.A....(I)

Big PHARMA / PhRMA hasta en la S.O.P.A....(I)

Stop Online Piracy Act /S.O.P.A.






Click sobre imagen para ampliar

Una infografía al estilo Quino explica los efectos de la Ley SOPA

11/01/2012 01:22:35 p.m. | Emen.- La organización derechoaleer.org realizó una infografía con el estilo del caricaturista argentino Quino, para ofrecer detalles sobre la Ley que discute el Parlamento estadounindese y que es señalada de amenazar Internet.



23 de enero Dia de Internet contra la Ley S.O.P.A




Gracias a mi amigo y compañero en la Fac. Farmacia/
Universidad Central de Venezuela (UCV) Prof. Victor de la Hoz

El "pipe_line" es para mujeres...

US drugmakers currently have 851 medicines in development for diseases which disproportionately affect women, says a new industry report.

The products, which are all now in human clinical trials or awaiting Food and Drug Administration (FDA) review, include 139 potential treatments for cancers affecting women - 91 for breast cancer, 49 for ovarian cancer and nine for cervical cancer, says the report, from the Pharmaceutical Research and Manufacturers of America (PhRMA).

There are also 114 potential new treatments for arthritis and musculoskeletal disorders, says the group, noting that 60% of US patients with some type of arthritis or related conditions are female. 83 new treatments are in R&D for Alzheimer's disease - two-thirds of the 5.4 million Americans living with the disease are women - and 72 for depression and anxiety, which affect almost twice as many women as men.

Ver más...

USA: Pharma 150.000 empleos perdidos...

PhRMA Statement on Health Care Reform
WASHINGTON, March 22

"Our commitment to help pay for health care reform will require all of our companies to make some difficult choices moving forward – on top of already losing more than 150,000 jobs since 2007 because of the recession and other economic factors.

Más

"Big Pharma" presiona FDA por "reglas claras" para Mktg. en la web...

NEW YORK (AdAge.com) --

Big Pharma is making one last push to the Food and Drug Administration urging the regulatory agency to quickly adopt new guidelines for marketing on the web and using social-media tools.

"Right now there are no internet-specific standards on how manufacturers can use these media," said Jeffrey K. Francer, assistant general counsel for the industry trade group Pharmaceutical Research and Manufacturers of America (PhRMA). "The lack of such standards is chilling the use of such technology."

.../...

PhRMA, Pfizer and Merck were among the many that beat the deadline and took advantage of the public comment period to be more expansive than a 10-minute speech. PhRMA sent the FDA a 16-page letter, issued a statement and held a conference call to reiterate its call for an FDA logo or link on an ad that would denote that the ad is regulated -- a sort of "Good Housekeeping" seal of approval -- and allow the user to one-click their way to safety information.

.../...

Merck's letter to the FDA was 12 pages long and advocated for the "one-click rule," and also called on the FDA to create a new panel to oversee the liquid nature of Web 2.0.

Ver

USA: PhRMA pide a FDA una certificación de calidad para internet...

WASHINGTON, Nov 9 (Reuters) - A drug industry group on Monday urged the U.S. Food and Drug Administration to adopt a universal safety symbol for Internet content containing FDA-approved information about a medicine or medical device.

The proposal from the Pharmaceutical Research and Manufacturers of America, which represents some of the biggest drug makers in the world, came ahead of an FDA public meeting this week on how FDA-regulated prescription drugs and medical devices are promoted in social media and on the Internet.

En España, el Colegio de Médicos de Cataluña fué pionero en este sentido creando Web médica acreditada.

USA: Big Pharma lobbying (II): Quién y cuanto...

Within this industry, the trade group Pharmaceutical Research and Manufacturers of America (PhRMA) leads the way on lobbying activities, spending more than $20.2 million last year, or $10,750 an hour that Congress was in session. Only six other companies in all sectors combined spent more on lobbying last year. Three other drug companies spent more than $10 million on lobbying in 2008: Eli Lilly, Pfizer and Amgen. Two-dozen others spent between $1 million and $7 million



Datos tomados de CRP.